BRPI1011527A2 - derivados de triazina substituídos com ureidofenil e suas aplicações terapêuticas. - Google Patents
derivados de triazina substituídos com ureidofenil e suas aplicações terapêuticas.Info
- Publication number
- BRPI1011527A2 BRPI1011527A2 BRPI1011527A BRPI1011527A BRPI1011527A2 BR PI1011527 A2 BRPI1011527 A2 BR PI1011527A2 BR PI1011527 A BRPI1011527 A BR PI1011527A BR PI1011527 A BRPI1011527 A BR PI1011527A BR PI1011527 A2 BRPI1011527 A2 BR PI1011527A2
- Authority
- BR
- Brazil
- Prior art keywords
- ureidophenyl
- therapeutic applications
- triazine derivatives
- substituted triazine
- substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18542709P | 2009-06-09 | 2009-06-09 | |
| PCT/US2010/037890 WO2010144522A1 (en) | 2009-06-09 | 2010-06-09 | Ureidophenyl substituted triazine derivatives and their therapeutical applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1011527A2 true BRPI1011527A2 (pt) | 2016-07-26 |
Family
ID=43309205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1011527A BRPI1011527A2 (pt) | 2009-06-09 | 2010-06-09 | derivados de triazina substituídos com ureidofenil e suas aplicações terapêuticas. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20120202818A1 (pt) |
| EP (1) | EP2440056A4 (pt) |
| JP (1) | JP2012529527A (pt) |
| KR (1) | KR20120016676A (pt) |
| CN (1) | CN102573481A (pt) |
| AU (1) | AU2010258825B2 (pt) |
| BR (1) | BRPI1011527A2 (pt) |
| CA (1) | CA2765050A1 (pt) |
| IL (1) | IL216829A0 (pt) |
| WO (1) | WO2010144522A1 (pt) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108524505A (zh) | 2009-03-13 | 2018-09-14 | 安吉奥斯医药品有限公司 | 用于细胞增殖相关病症的方法和组合物 |
| CN105175409A (zh) * | 2009-06-08 | 2015-12-23 | 南特生物科学公司 | 三嗪衍生物及其治疗应用 |
| CN102481300B (zh) | 2009-06-29 | 2015-04-15 | 安吉奥斯医药品有限公司 | 治疗性化合物和组合物 |
| ES2594402T3 (es) | 2009-10-21 | 2016-12-20 | Agios Pharmaceuticals, Inc. | Métodos y composiciones para trastornos relacionados con la proliferación celular |
| PL3406251T3 (pl) | 2011-05-03 | 2024-04-29 | Agios Pharmaceuticals, Inc. | Aktywatory kinazy pirogronianowej do stosowania w terapii |
| CN102250065B (zh) * | 2011-05-20 | 2015-05-13 | 浙江海正药业股份有限公司 | 取代的三嗪苯脲衍生物及其用途 |
| CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| JP2014525418A (ja) * | 2011-09-05 | 2014-09-29 | 浙江海正薬業股▲ふん▼有限公司 | タンパク質キナーゼ阻害活性を有する４−置換−（３−置換−１ｈ−ピラゾール−５−アミノ）−ピリミジン誘導体及びその使用 |
| EP2800743B1 (en) | 2012-01-06 | 2018-04-04 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| US9242977B2 (en) | 2012-04-26 | 2016-01-26 | Ono Pharmaceutical Co., Ltd. | Trk-inhibiting compound |
| NZ706999A (en) | 2012-10-15 | 2018-12-21 | Agios Pharmaceuticals Inc | Inhibitors of mutant isocitrate dehydrogenase and therapeutical uses thereof |
| WO2014129431A1 (ja) | 2013-02-19 | 2014-08-28 | 小野薬品工業株式会社 | Ｔｒｋ阻害化合物 |
| CA2949048A1 (en) | 2013-05-22 | 2014-11-27 | The Regents Of The University Of California | Aurora kinase inhibitors |
| CN111087353B (zh) * | 2013-07-11 | 2023-10-24 | 法国施维雅药厂 | 治疗活性化合物及其使用方法 |
| US9724350B2 (en) * | 2013-07-11 | 2017-08-08 | Agios Pharmaceuticals, Inc. | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CA2917671A1 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | 2,4-or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer |
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| KR20240010105A (ko) | 2014-03-14 | 2024-01-23 | 아지오스 파마슈티컬스 아이엔씨. | 치료적으로 활성인 화합물의 약제학적 조성물 |
| PT3307271T (pt) | 2015-06-11 | 2023-10-10 | Agios Pharmaceuticals Inc | Métodos de utilização de ativadores da piruvato-cinase |
| MX2018004586A (es) | 2015-10-15 | 2018-08-16 | Agios Pharmaceuticals Inc | Terapia de combinacion para tratar tumores malignos. |
| LT3362065T (lt) | 2015-10-15 | 2024-07-25 | Les Laboratoires Servier | Kompleksinė terapija, apimanti ivosidenibą, citarabiną ir daunorubiciną arba idarubiciną, skirta ūminės mielogeninės leukemijos gydymui |
| SG11201809760TA (en) | 2016-05-12 | 2018-12-28 | Nanjing Shiqi Pharmaceutical Co Ltd | Novel 2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| CA3190539A1 (en) * | 2020-08-26 | 2022-03-03 | William Greenlee | Modulators of myc family proto-oncogene protein |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7473691B2 (en) * | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6638926B2 (en) * | 2000-09-15 | 2003-10-28 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| CN100436452C (zh) * | 2000-12-21 | 2008-11-26 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的吡唑化合物 |
| AU2003225800A1 (en) * | 2002-03-15 | 2003-09-29 | Hayley Binch | Azolylaminoazine as inhibitors of protein kinases |
| AR037647A1 (es) * | 2002-05-29 | 2004-12-01 | Novartis Ag | Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina |
| US20050014753A1 (en) * | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
| AU2006311830B2 (en) * | 2005-11-03 | 2013-03-14 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
| WO2008076883A2 (en) * | 2006-12-15 | 2008-06-26 | Abraxis Bioscience, Inc. | Triazine derivatives and their therapeutical applications |
-
2010
- 2010-06-09 CA CA2765050A patent/CA2765050A1/en not_active Abandoned
- 2010-06-09 BR BRPI1011527A patent/BRPI1011527A2/pt not_active IP Right Cessation
- 2010-06-09 JP JP2012515092A patent/JP2012529527A/ja active Pending
- 2010-06-09 CN CN201080032850XA patent/CN102573481A/zh active Pending
- 2010-06-09 EP EP10786737A patent/EP2440056A4/en not_active Withdrawn
- 2010-06-09 US US13/376,818 patent/US20120202818A1/en not_active Abandoned
- 2010-06-09 AU AU2010258825A patent/AU2010258825B2/en active Active
- 2010-06-09 KR KR1020127000625A patent/KR20120016676A/ko not_active Application Discontinuation
- 2010-06-09 WO PCT/US2010/037890 patent/WO2010144522A1/en active Application Filing
-
2011
- 2011-12-07 IL IL216829A patent/IL216829A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010258825A1 (en) | 2012-01-12 |
| JP2012529527A (ja) | 2012-11-22 |
| CN102573481A (zh) | 2012-07-11 |
| AU2010258825B2 (en) | 2014-08-21 |
| EP2440056A1 (en) | 2012-04-18 |
| IL216829A0 (en) | 2012-02-29 |
| WO2010144522A1 (en) | 2010-12-16 |
| KR20120016676A (ko) | 2012-02-24 |
| US20120202818A1 (en) | 2012-08-09 |
| EP2440056A4 (en) | 2012-12-05 |
| CA2765050A1 (en) | 2010-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1011527A2 (pt) | derivados de triazina substituídos com ureidofenil e suas aplicações terapêuticas. | |
| BRPI1010881A2 (pt) | derivados de triazina e suas aplicações terapêuticas. | |
| BRPI1010882A2 (pt) | derivados de triazina e suas aplicações terapêuticas. | |
| BRPI1013642A2 (pt) | derivado de triazina e composição farmacêutica compreendendo o mesmo | |
| BRPI1008955A2 (pt) | Terapia de combinação com derivados de tiocolchicina. | |
| BRPI1016117A2 (pt) | derivados de isoxazol-isoxazol e isoxasol-isotiazol. | |
| BRPI1010887A2 (pt) | derivados de triazina e suas aplicações terapêuticas. | |
| BRPI1016150A2 (pt) | compostos heterocíclicos e seus usos. | |
| BRPI1008661A2 (pt) | derivados e remédios de aminopirazina | |
| BRPI1008749A2 (pt) | Derivados de benzodiazepina | |
| BRPI0920521A2 (pt) | combinação farmacêutica | |
| BRPI0914662A2 (pt) | derivados de triazinona substituída | |
| BRPI0914544A2 (pt) | derivados de pirimidona substituídos | |
| BR112012015868A2 (pt) | derivados de imidazolidinadiona | |
| BR112012010242A2 (pt) | derivados de heteroarilpiperidina e heteroarilpiperazina | |
| FR2947435B1 (fr) | Article cosmetique incluant une structure multicouche electrochromique. | |
| BRPI1011319A2 (pt) | derivados de triazina benzil-substituídos e suas aplicações terapêuticas | |
| BRPI0917446A2 (pt) | derivados de acilaminobenzamida. | |
| BRPI0906714A2 (pt) | Derivados de oxazepinopirimidona heteroarilamida substituídos. | |
| BRPI0909422A2 (pt) | conjunto de artigos. | |
| BRPI1016192A2 (pt) | derivados de soxazol. | |
| DK2442870T3 (da) | Pyrazinooxazepin-derivater. | |
| BRPI1011318A2 (pt) | derivados de triazina e suas aplicações terapêuticas | |
| BRPI1013716A2 (pt) | 5-alquinil-piridinas. | |
| BRPI1011320A2 (pt) | derivados de estiril-triazina e suas aplicações terapêuticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |